Promoter Methylation Pattern of Caspase-8, P16INK4A, MGMT, TIMP-3, and E-Cadherin in Medulloblastoma

Pathology and Oncology Research

Volumn 10, Issue 1, 2004, Pages 17-21

  Ebinger, Martin ^a   Senf, Leonore ^b   Wachowski, Olga ^c   Scheurlen, Wolfram ^b  

^a Institute of Pathology   (Germany)

^b Cnopf'sche Kinderklinik   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Aberrant promoter methylation; Caspase 8; CDH1; Medulloblastoma; MGMT; p16 INK4A; TIMP 3

Indexed keywords

CASPASE 8; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UVOMORULIN;

5' UNTRANSLATED REGION; ADOLESCENT; ARTICLE; BINDING SITE; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; CPG ISLAND; EMBRYO DEVELOPMENT; ENZYME ANALYSIS; ENZYME INACTIVATION; EWING SARCOMA; FEMALE; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; MALE; MEDULLOBLASTOMA; METHYLATION; NEURAL CREST; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 1942440046     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893403     Document Type: Article

References (27)

1. Bachman KE, Herman JG, Corn PG et al: Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res 59: 798-802, 1999.
2. Banelli B, Casciano I, Croce M et al: Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat Med 8: 1333-1335; author25 reply 1335, 2002.
3. Barker FG, Chen P, Furman F et al: P16 deletion and mutation analysis in human brain tumors. J Neurooncol 31: 17-23, 1997.
4. Berx G, Staes K, van Hengel J et al: Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 26: 281-289, 1995.
5. Bobola MS, Berger MS, Ellenbogen RG et al: O6-methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics. Clin Cancer Res 7: 613-619, 2001.
6. Bodmer JL, Holler N, Reynard S et al: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2: 241-243, 2000.
7. Costello JF, Frühwald MC, Smiraglia DJ et al: Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat Genet 25: 132-138, 2000
8. Esteller M, Sanchez-Cespedes M, Rosell R et al: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59: 67-70, 1999.
9. Esteller M, Garcia-Foncillas J, Andion E et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
10. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574-577, 1996.
11. Frühwald MC, O'Dorisio MS, Dai Z et al: Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - implications for tumor biology and potential clinical utility. Oncogene 36: 5033-5042, 2001.
12. Fulda S, Sieverts H, Friesen C et al: The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57: 3823-3829, 1997.
13. Fulda S, Debatin KM: IFN sensitizes for apoptosis by upregulating caspase-8 expression through the STAT1 pathway. Oncogene 15: 2295-2308, 2002.
14. Grenet J, Teitz T, Wei T et al: Structure and chromosome localization of the human CASP8 gene. Gene 226: 225-232, 1999.
15. Grotzer MA, Eggert A, Zuzak TJ et al: Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19: 4604-4610, 2000.
16. Harada K, Toyooka S, Shivapurkar N et al: Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62: 5897-5901, 2002.
17. Herman JG, Graff JR, Myohanen S et al: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
18. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
19. Katzenellenbogen RA, Baylin SB, Herman JG: Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93: 4347-4353, 1999.
20. Mannello F, Gazzanelli G: Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 6: 479-482, 2001.
21. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 16: 1215, 1988.
22. Packer RJ: Childhood medulloblastoma: progress and future challenges. Brain Dev 21: 75-81, 1999.
23. Ramchandani S, MacLeod AR, Pinard M et al: Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 94: 684-689, 1997.
24. Schutz BR, Scheurlen W, Krauss J et al: Mapping of chromosomal gains and losses in primitive neuroectodermal tumors by comparative genomic hybridization. Genes Chromosomes Cancer 16: 196-203, 1996.
25. Teitz T, Wei T, Valentine MB et al: Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535, 2000.
26. Zöchbauer-Müller S, Fong KM, Virmani AK et al: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255, 2001.
27. Zuzak TJ, Steinhoff DF, Sutton LN et al: Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur J Cancer 38: 83-91, 2002.